BioSpace News Archive

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, announces the recipients of the 2022 Emerging Leader Awards, which are designed to support promising scientists who are advancing development of accurate and effective diagnostic tests.

Cohen Children’s Medical Center announced the opening of the Pediatric Surgical Operating Complex, a $110 million, 24,000-square-foot, state-of-the-art home for pediatric surgery that greatly enhances the capabilities of New York State’s No. 1 provider of pediatric health services and largest Level 1 pediatric trauma center.

Mindray North America, a global leader and developer of healthcare technologies and solutions for ultrasound, patient monitoring, and anesthesia, announced the launch of a new product that is changing the perspective in the Point of Care Ultrasound market: the TE X Ultrasound System.

Trethera Corporation (“Trethera”), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022.

Heron Therapeutics, Inc. announced today that it has entered into a securities purchase agreement to sell in a private placement to a group of new and existing institutional investors.

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the company’s Phase 2 COMPASS Osteoarthritis Pain Trial.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that it has received approximately $3.6 million in net proceeds following an exercise of Series B warrants by an institutional investor in the Company.

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Thomas M. Soloway to its Board of Directors.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines.